2.11 USD
-0.06 (-2.76%)
Overall AMS gets a fundamental rating of 2 out of 10. We evaluated AMS against 101 industry peers in the Health Care Providers & Services industry. AMS may be in some trouble as it scores bad on both profitability and health. AMS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
AMS had negative earnings in the past year.
In the past year AMS had a positive cash flow from operations.
Of the past 5 years AMS 4 years were profitable.
Each year in the past 5 years AMS had a positive operating cash flow.
1.2 Ratios
AMS has a Return On Assets of -3.84%. This is in the lower half of the industry: AMS underperforms 65.35% of its industry peers.
AMS has a Return On Equity of -9.97%. This is comparable to the rest of the industry: AMS outperforms 43.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| ROIC | N/A |
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AMS's Profit Margin has improved in the last couple of years.
In the last couple of years the Operating Margin of AMS has declined.
AMS has a Gross Margin (24.43%) which is in line with its industry peers.
In the last couple of years the Gross Margin of AMS has remained more or less at the same level.
AMS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.43% |
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
2. Health
2.1 Basic Checks
AMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AMS has more shares outstanding
AMS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.85, we must say that AMS is in the distress zone and has some risk of bankruptcy.
AMS has a worse Altman-Z score (0.85) than 73.27% of its industry peers.
AMS has a Debt/Equity ratio of 0.58. This is a neutral value indicating AMS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.58, AMS is in line with its industry, outperforming 59.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.85 |
ROIC/WACCN/A
WACC9.46%
2.3 Liquidity
AMS has a Current Ratio of 1.17. This is a normal value and indicates that AMS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.17, AMS is in line with its industry, outperforming 41.58% of the companies in the same industry.
AMS has a Quick Ratio of 1.17. This is a normal value and indicates that AMS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AMS (1.17) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for AMS have decreased strongly by -950.00% in the last year.
AMS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.28% yearly.
AMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.90%.
The Revenue has been growing slightly by 6.58% on average over the past years.
EPS 1Y (TTM)-950%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%100%
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%2.46%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.5%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.31%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
AMS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMS is cheaper than 96.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.49 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for AMS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:AMS (11/26/2025, 8:15:34 PM)
2.11
-0.06 (-2.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners13.68%
Inst Owner Change-2.58%
Ins Owners35.53%
Ins Owner Change4.52%
Market Cap13.74M
Revenue(TTM)28.34M
Net Income(TTM)-2.44M
Analysts80
Price Target4.59 (117.54%)
Short Float %0.41%
Short Ratio0.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.21%
Min EPS beat(2)0.99%
Max EPS beat(2)43.42%
EPS beat(4)2
Avg EPS beat(4)-543.23%
Min EPS beat(4)-2080.2%
Max EPS beat(4)43.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-3.97%
Max Revenue beat(2)-0.96%
Revenue beat(4)1
Avg Revenue beat(4)0.93%
Min Revenue beat(4)-7.97%
Max Revenue beat(4)16.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.47 | ||
| P/FCF | N/A | ||
| P/OCF | 4.77 | ||
| P/B | 0.56 | ||
| P/tB | 0.59 | ||
| EV/EBITDA | 3.49 |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)0.44
OCFY20.94%
SpS4.49
BVpS3.76
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.43% | ||
| FCFM | N/A |
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)6.05%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 182.58% | ||
| Cap/Sales | 39.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 46.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 0.85 |
F-Score4
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)86.06%
Cap/Depr(5y)59.68%
Cap/Sales(3y)19.8%
Cap/Sales(5y)14.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-950%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%100%
EPS Next Y49.5%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%2.46%
Revenue Next Year9.31%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.77%
EBIT growth 3Y-6.85%
EBIT growth 5Y-9.07%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-255.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.59%
OCF growth 3Y-70.14%
OCF growth 5Y-53.93%
AMERICAN SHARED HOSPITAL SER / AMS FAQ
What is the fundamental rating for AMS stock?
ChartMill assigns a fundamental rating of 2 / 10 to AMS.
Can you provide the valuation status for AMERICAN SHARED HOSPITAL SER?
ChartMill assigns a valuation rating of 1 / 10 to AMERICAN SHARED HOSPITAL SER (AMS). This can be considered as Overvalued.
How profitable is AMERICAN SHARED HOSPITAL SER (AMS) stock?
AMERICAN SHARED HOSPITAL SER (AMS) has a profitability rating of 3 / 10.
Can you provide the financial health for AMS stock?
The financial health rating of AMERICAN SHARED HOSPITAL SER (AMS) is 2 / 10.